| Schedule of Outstanding Warrants to Purchase Common Stock Issued to Stockholders |
As of March 31, 2025, the Company had
the following outstanding warrants to purchase Common Stock issued to stockholders:
| Warrant |
| Issuance Date |
| Expiration
Date |
| Exercise
Price
Per Share |
|
| Number of
Shares of
Common Stock
Underlying
Warrants |
|
| 2021 Registered Direct Offering Warrants |
| SPA (July 28, 2021) |
| January 28, 2027 |
| |
50.00 |
|
| |
281,251 |
|
| Merger Warrants |
| March 15, 2024 |
| January 28, 2027 |
| |
50.00 |
|
| |
216,650 |
|
| Private Placement Warrants |
| March 15, 2024 |
| July 9, 2026 |
| |
2.31 |
|
| |
3,865,322 |
|
| Registered Pre-Funded Warrants |
| February 25, 2025 |
| April 21, 2030 |
| |
0.0001 |
|
| |
805,231 |
|
| Private Pre-Funded Warrants |
| February 25, 2025 |
| April 21, 2030 |
| |
0.0001 |
|
| |
2,305,869 |
|
| Common Warrants |
| February 25, 2025 |
| April 21, 2030 |
| |
0.9306 |
|
| |
5,939,383 |
|
| Inducement Warrants |
| February 25, 2025 |
| April 21, 2030 |
| |
0.9306 |
|
| |
6,955,528 |
|
| A&R Warrants |
| February 25, 2025 |
| April 21, 2030 |
| |
0.0001 |
|
| |
2,994,419 |
|
| |
| |
| |
| |
|
|
| |
23,363,653 |
|
|
| Schedule of Stock Option Plans |
A
summary of options granted to purchase the Company’s Common Stock under the Company’s share option plans is as follows:
| |
| For the Three Months Ended
March 31, 2025 |
|
| |
| Number of
Options |
|
| Weighted
Average
Exercise
Price |
|
| Aggregate
Intrinsic
Value |
|
| Outstanding at the beginning of period |
| |
2,002,365 |
|
| |
4.09 |
|
| |
15 |
|
| Granted |
| |
- |
|
| |
- |
|
| |
|
|
| Forfeited |
| |
(45,810 |
) |
| |
3.63 |
|
| |
|
|
| Expired |
| |
(32,874 |
) |
| |
2.85 |
|
| |
|
|
| Exercised |
| |
- |
|
| |
- |
|
| |
|
|
| Outstanding at the end of period |
| |
1,923,681 |
|
| |
4.12 |
|
| |
11 |
|
| Exercisable at the end of period |
| |
353,482 |
|
| |
6.09 |
|
| |
|
|
| Weighted average remaining contractual life of outstanding options – years as of March 31, 2025 |
| |
8.40 |
|
| |
|
|
| |
|
|
|
| Schedule of Outstanding Compensation Related Warrants to Purchase Common Stock |
As of March 31, 2025, the Company had
the following outstanding compensation related warrants to purchase Common Stock:
| Warrant |
| Issuance
Date |
| Expiration
Date |
|
| Exercise
Price
Per Share |
|
| Number of
Shares of
Common Stock
Underlying
Warrants |
|
| Private Warrants issued to scientific founders |
| November 27, 2017 |
| |
- |
|
| |
- |
|
| |
298 |
|
| Landlord Warrants |
| March 15, 2024 |
| |
January 28, 2027 |
|
| |
50.00 |
|
| |
25,000 |
|
| Agents Warrants |
| March 15, 2024 |
| |
July 9, 2026 |
|
| |
2.31 |
|
| |
952,381 |
|
| |
| |
| |
|
|
| |
|
|
| |
977,679 |
|
|
| Schedule of Stock-Based Payment Expenses |
The
following table sets forth the total stock-based payment expenses resulting from options granted, included in the statements of operations:
| |
|
Three Months Ended
March 31, |
|
| |
|
2025 |
|
|
2024 |
|
| Research and development expenses, net |
|
|
188 |
|
|
|
65 |
|
| General and administrative |
|
|
471 |
|
|
|
112 |
|
| |
|
|
659 |
|
|
|
177 |
|
|